دورية أكاديمية
International consensus on mitotane treatment in pediatric patients with adrenal cortical tumors: indications, therapy, and management of adverse effects.
| العنوان: | International consensus on mitotane treatment in pediatric patients with adrenal cortical tumors: indications, therapy, and management of adverse effects. |
|---|---|
| المؤلفون: | Riedmeier M; University Hospital Würzburg, Department of Pediatrics, Division of Pediatric Hematology, Oncology and Stem Cell Transplantation, University of Wuerzburg, Wuerzburg 97080, Germany., Antonini SRR; Department of Pediatrics, Ribeirao Preto Medical School, University of Sao Paulo, Ribeirao Preto, Sao Paulo 14051-200, Brazil., Brandalise S; Boldrini Children's Hospital, Department of Pediatrics, São Paulo 13083-210, Brazil., Costa TEJB; Service of Pediatric Oncology, Hospital Infantil Joana de Gusmão, Florianópolis, SC 88025-301, Brazil., Daiggi CM; Boldrini Children's Hospital, Department of Pediatrics, São Paulo 13083-210, Brazil., de Figueiredo BC; Instituto de Pesquisa Pelé Pequeno Príncipe, Curitiba 80250-060, Brazil., de Krijger RR; Department of Pathology, University Medical Center Utrecht, Utrecht 3584 CS, The Netherlands., De Sá Rodrigues KE; Pediatric Department, Barretos Cancer Hospital, São Paulo 14784-400, Brazil., Deal C; Research Center, CHU Sainte-Justine and University of Montreal, Montreal, Québec H3T 1C5, Canada., Del Rivero J; Developmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, United States., Engstler G; St. Anna Kinderspital, Department of Pediatrics, Medical University Vienna, Vienna 1090, Austria., Fassnacht M; Department of Medicine, Division of Endocrinology and Diabetes, University Hospital, University of Wuerzburg, Wuerzburg 97080, Germany., Fernandes Luiz Canali GC; Oncologia, Pequeno Principe Hospital, Curitiba 80250-060, PR, Brazil., Molina CAF; Department of Surgery and Anatomy, Ribeirao Preto Medical School, University of Sao 15 Paulo, Ribeirao Preto, Sao Paulo 14049-900, Brazil., Gonc EN; Department of Pediatric Endocrinology, Faculty of Medicine, Hacettepe University, Ankara 06230, Turkey., Gültekin M; Department of Radiation Oncology, Faculty of Medicine, Hacettepe University, Ankara 06100, Turkey., Haak HR; Department of Internal Medicine, Máxima MC, Eindhoven 5631 BM/Veldhoven 5504 DB, The Netherlands.; CAPHRI School for Public Health and Primary Care, Ageing and Long-Term Care, Maastricht University, Maastricht 616 6200 MD, The Netherlands., Guran T; Department of Paediatric Endocrinology and Diabetes, Marmara University School of Medicine, Istanbul 34722, Turkey., Hendriks Allaird EJ; Department of Paediatrics, University of Cambridge, Cambridge CB20QQ, United Kingdom.; Department of Paediatric Endocrinology and Diabetes, Cambridge University Hospitals NHS Foundation Trust, Cambridge CB20QQ, United Kingdom., Idkowiak J; Institute of Metabolism and Systems Research, College of Medical and Dental Sciences, University of Birmingham, Birmingham B152TT, United Kingdom.; Department of Endocrinology, Birmingham Women's and Children's Hospital NHS Foundation Trust, Birmingham B46NH, United Kingdom., Kuhlen M; Pediatrics and Adolescent Medicine, Faculty of Medicine, University of Augsburg, Augsburg 86135, Germany., Malkin D; Division of Haematology/Oncology, The Hospital for Sick Children, University of Toronto, Toronto, Ontario M5G1X8, Canada., Meena JP; Division of Pediatric Oncology, Department of Pediatrics, Mother & Child Block, All India Institute of Medical Sciences, New Delhi 110029, India., Pamporaki C; Department of Medicine III, University Hospital Carl Gustav Carus, TU Dresden, Dresden 01307, Germany., Pinto E; St. Jude Children's Research Hospital, Memphis, TN 38105, United States., Puglisi S; Internal Medicine, Department of Clinical and Biological Sciences, San Luigi Gonzaga Hospital, University of Turin, Orbassano 10043, Italy., Ribeiro RC; Department of Oncology, St Jude Children's Research Hospital, Memphis, TN 38105, United States., Thompson LDR; Pathology, Head and Neck Pathology Consultations, Woodland Hills, CA 91364, United States., Yalcin B; Department of Pediatric Oncology, Faculty of Medicine, Hacettepe University, Ankara 06230, Turkey., Van Noesel M; Pediatric Oncology, Princess Máxima Center for Pediatric Oncology, Utrecht 3584 CS, The Netherlands.; Division Imaging & Cancer, University Medical Center Utrecht, Utrecht 3584 CS, The Netherlands., Wiegering V; University Hospital Würzburg, Department of Pediatrics, Division of Pediatric Hematology, Oncology and Stem Cell Transplantation, University of Wuerzburg, Wuerzburg 97080, Germany. |
| المصدر: | European journal of endocrinology [Eur J Endocrinol] 2024 Mar 30; Vol. 190 (4), pp. G15-G24. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Oxford University Press Country of Publication: England NLM ID: 9423848 Publication Model: Print Cited Medium: Internet ISSN: 1479-683X (Electronic) Linking ISSN: 08044643 NLM ISO Abbreviation: Eur J Endocrinol Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: 2023- : Oxford : Oxford University Press Original Publication: Oslo, Norway : Scandinavian University Press, c1994- |
| مواضيع طبية MeSH: | Adrenocortical Carcinoma*/drug therapy , Adrenocortical Carcinoma*/pathology , Adrenal Cortex Neoplasms*/drug therapy , Adrenal Cortex Neoplasms*/pathology , Drug-Related Side Effects and Adverse Reactions*, Humans ; Child ; Mitotane/adverse effects ; Antineoplastic Agents, Hormonal/adverse effects |
| مستخلص: | Objective: Mitotane is an important cornerstone in the treatment of pediatric adrenal cortical tumors (pACC), but experience with the drug in the pediatric age group is still limited and current practice is not guided by robust evidence. Therefore, we have compiled international consensus statements from pACC experts on mitotane indications, therapy, and management of adverse effects. Methods: A Delphi method with 3 rounds of questionnaires within the pACC expert consortium of the international network groups European Network for the Study of Adrenal Tumors pediatric working group (ENSAT-PACT) and International Consortium of pediatric adrenocortical tumors (ICPACT) was used to create 21 final consensus statements. Results: We divided the statements into 4 groups: environment, indications, therapy, and adverse effects. We reached a clear consensus for mitotane treatment for advanced pACC with stages III and IV and with incomplete resection/tumor spillage. For stage II patients, mitotane is not generally indicated. The timing of initiating mitotane therapy depends on the clinical condition of the patient and the setting of the planned therapy. We recommend a starting dose of 50 mg/kg/d (1500 mg/m²/d) which can be increased up to 4000 mg/m2/d. Blood levels should range between 14 and 20 mg/L. Duration of mitotane treatment depends on the clinical risk profile and tolerability. Mitotane treatment causes adrenal insufficiency in virtually all patients requiring glucocorticoid replacement shortly after beginning. As the spectrum of adverse effects of mitotane is wide-ranging and can be life-threatening, frequent clinical and neurological examinations (every 2-4 weeks), along with evaluation and assessment of laboratory values, are required. Conclusions: The Delphi method enabled us to propose an expert consensus statement, which may guide clinicians, further adapted by local norms and the individual patient setting. In order to generate evidence, well-constructed studies should be the focus of future efforts. Competing Interests: Conflict of interest: None declared. (© The Author(s) 2024. Published by Oxford University Press on behalf of European Society of Endocrinology. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.) |
| معلومات مُعتمدة: | Z-02CSP/23 IZKF; 314061271-TRR 205 DFG German Research Foundation |
| فهرسة مساهمة: | Keywords: adrenal cortical carcinoma; mitotane therapy; pediatric adrenal cortical cancer; pediatric adrenal cortical carcinoma; pediatric adrenal cortical tumor |
| المشرفين على المادة: | 78E4J5IB5J (Mitotane) 0 (Antineoplastic Agents, Hormonal) |
| تواريخ الأحداث: | Date Created: 20240329 Date Completed: 20240417 Latest Revision: 20240417 |
| رمز التحديث: | 20240417 |
| DOI: | 10.1093/ejendo/lvae038 |
| PMID: | 38552173 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 1479-683X |
|---|---|
| DOI: | 10.1093/ejendo/lvae038 |